Non-invasive leadership FibroScan non-invasive liver assessment stands as the core product, offering a cost-effective alternative to biopsies. This presents a sales opportunity to hospitals and clinics seeking patient-friendly, guideline-supported liver disease management solutions.

Regulatory credibility FDA clearance and strong peer-reviewed support underpin market trust. Use this to approach procurement and clinical leadership emphasizing evidence-based adoption and alignment with established liver disease practice guidelines.

Clinical collaboration Past and ongoing CCM program development signals potential partnerships with gastroenterology and hepatology departments. Target clinician champions and clinical coordinators to expand adoption and integration into NAFLD/NASH management workflows.

Growth opportunity Small-to-mid-sized market footprint with revenue under one million indicates room for rapid expansion through multi-site clinics, ambulatory centers, and specialty labs seeking scalable liver health diagnostics.

Tech-enabled reach Digital presence and tech stack optimized for content delivery and support (Drupal, WordPress, cloud hosting) offer a channel for education, remote demonstrations, and post-sale support to drive adoption and training.